Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DZBV67
|
|||
| Drug Name |
BI 765063
|
|||
| Synonyms |
OSE-172
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Boehringer Ingelheim; OSE Immunotherapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Inhibitory receptor SHPS-1 (SIRPA) | Target Info | Antagonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04653142) A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of OSE Immunotherapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.